U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765498) titled 'A Study of LY4355756 in Healthy Participants' on Aug. 11.

Brief Summary: The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants.

There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: LY4355756

Administered orally as capsule

DRUG: LY4355756

Administered orally as tablet

DRUG: Midazolam

A...